ClinicalTrials.gg
CompletedNCT02791763Updated May 18, 2021Results posted

Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia

A Phase 3 interventional study of 1 to 4 mg tablets of GSK1278863 and 6 mg GSK1278863 tablet in Anaemia, sponsored by GlaxoSmithKline. Completed at 56 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-05-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
355
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
5th of 30
355 · median 76
Started
2016
with 4 others
Phase 3
9 of 30
1 open now
Registered
14th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 5th largest by enrollment, is one of 5 that started in 2016, is one of 9 in phase 3, and was the 14th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

This is a Phase III, open-label, active-controlled, parallel-group, multi-center study to compare the efficacy and safety of GSK1278863 administered for 52 weeks versus epoetin beta pegol in approximately 286 Japanese ND and 50 PD subjects with renal anemia. The study will consist of three cohorts. Cohort 1 and Cohort 3 will consist of ND subjects (Erythropoiesis-Stimulating Agent [ESA] users and ESA non-users) randomized to receive GSK1278863 or epoetin beta pegol in a ratio of 1:1. PD subjects will be enrolled into Cohort 2 and will receive GSK1278863. This study consists of a 4-week screening phase, a 52-week treatment phase (including primary efficacy evaluation period [Weeks 40 to 52]), and a 4-week follow-up phase following the treatment phase. The primary objective of this study is to demonstrate non-inferiority of GSK1278863 to epoetin beta pegol based on mean hemoglobin (Hgb) during the primary efficacy evaluation period in ND subjects. ESA non-users from Cohort 1 will be excluded from the primary efficacy analysis. Study results will be used as pivotal study data for an NDA submitted for GSK1278863 for the treatment of renal anemia in Japan.

03

Conditions studied

  • Anaemia

Keywords

  • Renal Anemia
  • Japanese
  • chronic kidney disease
  • Peritoneal dialysis
  • GSK1278863
  • Non-dialysis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age (at the time of ): >=20 years of age
  • Screening verification only: Stage of chronic kidney disease (CKD) (ND subjects only): CKD stages 3, 4, and 5 defined by estimated (eGFR) using the Japanese Society of Nephrology-Chronic Kidney Disease Initiatives (JSN-CKDI) formula
  • Dialysis:

    • Not on dialysis for at least 12 weeks prior to screening (ND subjects)
    • On peritoneal dialysis (PD subjects)
  • Use of ESA:

    • ESA non-users: Have not used ESAs for 8 weeks prior to screening
    • ESA users: Have used the same ESA for 8 weeks prior to screening. However, in the ND subjects, the dose of darbepoetin alfa or epoetin beta pegol must be stable (administered once every 4 weeks and up to one-step dose change during 8 weeks prior to screening).
  • : Determined at the site using an Hgb analyzer

    • ESA non-users: >=8.0 g/dL and \<11.0 g/dL
    • ESA users: >=9.0 g/dL and \<=13.0 g/dL
  • Iron parameters: Ferritin >100 nanograms per milliliters (ng/mL) or transferrin saturation (TSAT) >20% (screening verification only)
  • Gender (screening verification only): Female or male. Females: Not pregnant [demonstrated to be negative for human chorionic gonadotropin (hCG) in urine or serum], not breast-feeding, and meet at least one of the following:

    1. Females of non- are defined as follows:

      • Pre-menopausal with at least one of the following and no plans to utilize assisted reproductive techniques (e.g., in vitro fertilization or donor embryo transfer):
      • History of bilateral tubal ligation or salpingectomy
      • History of hysteroscopic tubal occlusion and postoperatively documented bilateral tubal obstruction
      • History of hysterectomy
      • History of bilateral oophorectomy
      • defined as: females 60 years of age or older or ; In females \<60 years of age, 12 months of spontaneous amenorrhea (in questionable cases a blood sample with postmenopausal follicle stimulating hormone [FSH] and estradiol concentrations is confirmatory [specified reference ranges]). Females on hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use one of the most effective methods if they wish to continue their HRT during the study. Otherwise they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
    2. Females of childbearing potential must agree to comply with one of the contraception methods listed as requirements in "GSK Listing of Most Effective Contraceptive Methods for Females of Childbearing Potential" from 28 days prior to the first dose of study medication until the completion of the follow-up visit (for subjects randomized to the GSK1278863 group) or 7 weeks after the last dose of study treatment (for subjects randomized to the Epoetin beta pegol group).
  • Informed consent: Written informed consent, including adherence to the requirements and conditions specified in the consent form and the protocol, must be obtained from each subject as specified in Protocol.

Exclusion criteria

Exclusion Criteria:

Chronic kidney disease (CKD)-related criteria

  • Dialysis

    • Cohort 1 and Cohort 3: Start or plan to initiate dialysis during the study
    • Cohort 2: Plan to stop peritoneal dialysis or start hemodialysis during the study
  • Kidney transplant: Planned living-related kidney transplant during the study Anemia-related criteria
  • Aplasia: History of bone-marrow hypoplasia or pure red cell aplasia
  • Other causes of anemia: pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes
  • Gastrointestinal (GI) bleeding: Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease OR GI bleeding within 8 weeks prior to screening or during a period from screening to Day 1.

Cardiovascular disease-related criteria

  • Myocardial infarction, acute coronary syndrome, stroke, or : Diagnosed within 8 weeks prior to screening or during a period from screening to Day 1.
  • Heart failure: Class IV heart failure, as defined by the (NYHA) functional classification system
  • corrected for heart rate (QTc) (screening verification only): QTc >500 milliseconds (msec) or QTc >530 msec in subjects with bundle branch block Note: QT interval corrected using the Bazett's formula (QTcB) will be used, and (ECG) can be mechanically or manually read.

Other disease-related criteria

  • Liver disease (if any of the following occurs):

    • (Screening verification only) (ALT) >2 times (ULN)
    • (Screening verification only) >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%)
    • Current unstable active liver or biliary disease (generally defined by the onset of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, persistent jaundice, or cirrhosis) Note: Stable liver disease (including asymptomatic gallstones, chronic /C, or Gilbert's syndrome) is acceptable if the subject otherwise meets entry criteria..
  • : History of malignancy within 2 years prior to screening, or currently receiving treatment for cancer, (PD subjects only) complex renal cystic >3 centimeters (cm) (II F, III or IV based on the Bosniak classification) Note (ND subjects and PD subjects): The only exception is squamous cell or basal cell carcinoma of the skin that has been definitively treated >=8 weeks before screening.
  • In the opinion of the investigator, increase to the target range (11.0-13.0 g/dL) is medically risky.

Concomitant medication and other study treatment-related criteria

  • Iron: Planned use of intravenous iron during the screening phase or during a period from Day 1 to Week 4 Note: Oral iron is acceptable. However, the same dose regimen must be used throughout the screening phase and from Day 1 to Week 4. Antihyperphosphatemic agents containing iron (e.g., ferric citrate hydrate) are also acceptable only if used for at least 12 weeks prior to screening. However, they must be continued throughout the screening phase from Day 1 to Week 4.
  • Severe allergic reactions: History of severe allergic or anaphylactic reactions or to in the product or epoetin beta pegol
  • Drugs and supplements: Use or planned use of any prescription or non-prescription drugs or dietary supplements that are prohibited during the study period (prohibited medications: strong inducers and inhibitor of Cytochrome P450 2C8 [CYP2C8])
  • Prior investigational product exposure: Use of an investigational agent within 30 days or five half lives of the investigational agent (whichever is longer)
  • Prior treatment with GSK1278863: Any prior treatment with GSK1278863 for a treatment duration of >30 days

General health-related criteria

  • Other conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the investigator (or subinvestigator) considers would put the subject at unacceptable risk, which may affect study compliance or prevent understanding of the aims or investigational procedures or possible consequences of the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
355 participants (actual)

Study arms

  • Experimental
    Daprodustat in ND participants

    Eligible ND participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 milligrams \[mg\] as recommended) dose once daily for 52 weeks.

    Drug: 1 to 4 mg tablets of GSK1278863 · Drug: 6 mg GSK1278863 tablet

  • Active comparator
    Epoetin beta pegol in ND participants

    Eligible ND participants will receive subcutaneous (SC) epoetin beta pegol (25, 50, 75, 100, 150, 200 or 250 microgram \[µg\] as recommended) dose once every 2 or 4 weeks for 52 weeks.

    Drug: Epoetin beta pegol

  • Experimental
    Daprodustat in PD participants

    Eligible PD participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 mg as recommended) dose once daily for 52 weeks.

    Drug: 1 to 4 mg tablets of GSK1278863 · Drug: 6 mg GSK1278863 tablet

Interventions

  • Drug1 to 4 mg tablets of GSK1278863

    7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.

  • 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.

  • An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.

06

What researchers measure

Primary outcomes

  1. Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants

    The mean hemoglobin during the primary efficacy evaluation period in ND participants was estimated by a statistical model using Mixed Model Repeated Measures (MMRM).

    Time frame: Weeks 40 to 52

Secondary outcomes

  1. Number of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)

    ND participants with observed mean Hgb within the target range during the primary efficacy evaluation period were summarized. Responders were defined as the participants with the mean Hgb within target range during the primary efficacy evaluation period.

    Time frame: Weeks 40 to 52

  2. Percentage of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)

    The percentage of ND participants with observed mean Hgb within the target range during the primary efficacy evaluation period was summarized. Responders were defined as the participants with the mean Hgb within target range during the primary efficacy evaluation period.

    Time frame: Weeks 40 to 52

  3. Change From Baseline in Hgb at Week 4 in ND Participants

    Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb at Week 4 in ND participants is presented.

    Time frame: Baseline (Day 1) and Week 4

  4. Change From Baseline in Hgb at Week 4 in PD Participants

    Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb at week 4 in PD participants is presented.

    Time frame: Baseline (Day 1) and Week 4

  5. Number of ND Participants by Hgb Change From Baseline Category at Week 4

    Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.

    Time frame: Baseline (Day 1) and Week 4

  6. Percentage of ND Participants by Hgb Change From Baseline Category at Week 4

    Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.

    Time frame: Baseline (Day 1) and Week 4

  7. Number of PD Participants by Hgb Change From Baseline Category at Week 4

    Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.

    Time frame: Baseline (Day 1) and Week 4

  8. Percentage of PD Participants by Hgb Change From Baseline Category at Week 4

    Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.

    Time frame: Baseline (Day 1) and Week 4

  9. Daprodustat Dose Level by Visit in ND Participants

    Daprodustat dose level at each assessment visit for ND participants is presented using 25th percentile (P25), median, and 75th percentile (P75).

    Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44 and 48

  10. Epoetin Beta Pegol Dose Level by Visit in ND Participants

    Dose of epoetin beta pegol at a scheduled visit was converted to dose per 4 weeks when the dose frequency was every 2 weeks. Epoetin beta pegol dose level at each assessment visit for ND participants is presented using 25th percentile (P25), median, and 75th percentile (P75).

    Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44 and 48

  11. Daprodustat Dose Level by Visit in PD Participants

    Daprodustat dose level at each assessment visit for PD participants is presented using 25th percentile (P25), median, and 75th percentile (P75).

    Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44 and 48

  12. Duration of Treatment Interruption Due to Hgb >13 g/dL in ND Participants

    The duration (in days) of treatment interruption due to Hgb \>13 g/dL per participant was summarized descriptively on participants with a period of treatment interruption due to Hgb \>13 g/dL.

    Time frame: Up to Week 52

  13. Duration of Treatment Interruption Due to Hgb >13 g/dL in PD Participants

    The duration (in days) of treatment interruption due to Hgb \>13 g/dL per participant was summarized descriptively on participants with a period of treatment interruption due to Hgb \>13 g/dL.

    Time frame: Up to Week 52

  14. Number of Dose Adjustments in ND Participants

    Number of dose adjustments in ND participants is presented.

    Time frame: Up to Week 52

  15. Number of Dose Adjustments in PD Participants

    Number of dose adjustments in PD participants is presented.

    Time frame: Up to Week 52

  16. Hgb Values at Each Assessment Visit in ND Participants

    Hgb values at each assessment visit for ND participants is presented.

    Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52

  17. Hgb Values at Each Assessment Visit in PD Participants

    Hgb values at each assessment visit for PD participants is presented.

    Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52

  18. Change From Baseline in Hgb Values at Each Assessment Visit in ND Participants

    Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb values at each assessment visit in ND participants is presented.

    Time frame: Baseline (Day 1), Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52

  19. Change From Baseline in Hgb Values at Each Assessment Visit in PD Participants

    Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb values at each assessment visit in PD participants is presented.

    Time frame: Baseline (Day 1), Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52

  20. Number of ND Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit

    Number of ND participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.

    Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52

  21. Percentage of ND Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit

    Percentage of ND participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.

    Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52

  22. Number of PD Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit

    Number of PD participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.

    Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52

  23. Percentage of PD Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit

    Percentage of PD participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.

    Time frame: Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52

  24. Percentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants

    Mean percentage of time with Hgb within the target range (11.0 to 13.0 g/dL) is summarized during the primary efficacy evaluation period (Weeks 40 to 52).

    Time frame: Weeks 40 to 52

  25. Percentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in PD Participants

    Mean percentage of time with Hgb within the target range (11.0 to 13.0 g/dL) is summarized during the primary efficacy evaluation period (Weeks 40 to 52).

    Time frame: Weeks 40 to 52

  26. Time to Reach the Lower Target Hgb Level (11.0 g/dL) in ND Participants

    The time (in days) to reach the lower target Hgb level (11.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method. Participants who did not reach the lower Hgb target were considered as censored cases. Participants who were randomized as Hgb \>= 11.0 g/dL were excluded in this summary.

    Time frame: Up to week 52

  27. Time to Reach the Lower Target Hgb Level (11.0 g/dL) in PD Participants

    The time (in days) to reach the lower target Hgb level (11.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method. Participants who did not reach the lower Hgb target were considered as censored cases. Participants who were randomized as Hgb \>= 11.0 g/dL were excluded in this summary.

    Time frame: Up to week 52

  28. Number of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL

    Number of ND participants who had an Hgb level of less than 7.5 g/dL is presented.

    Time frame: Up to week 52

  29. Percentage of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL

    Percentage of ND participants who had an Hgb level of less than 7.5 g/dL is presented.

    Time frame: Up to week 52

  30. Number of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL

    Number of PD participants who had an Hgb level of less than 7.5 g/dL is presented.

    Time frame: Up to week 52

  31. Percentage of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL

    Percentage of PD participants who had an Hgb level of less than 7.5 g/dL is presented.

    Time frame: Up to week 52

  32. Number of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

    Number of ND participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.

    Time frame: Up to week 52

  33. Percentage of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

    Percentage of ND participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.

    Time frame: Up to week 52

  34. Number of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

    Number of PD participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.

    Time frame: Up to week 52

  35. Percentage of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

    Percentage of PD participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.

    Time frame: Up to week 52

  36. Number of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL

    Number of ND participants who had an Hgb level of more than 13.0 g/dL is presented.

    Time frame: Up to week 52

  37. Percentage of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL

    Percentage of ND participants who had an Hgb level of more than 13.0 g/dL is presented.

    Time frame: Up to week 52

  38. Number of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL

    Number of PD participants who had an Hgb level of more than 13.0 g/dL is presented.

    Time frame: Up to week 52

  39. Percentage of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL

    Percentage of PD participants who had an Hgb level of more than 13.0 g/dL is presented.

    Time frame: Up to week 52

  40. Number of Episodes With Hgb Level of More Than 13.0 g/dL in ND Participants

    Number of episodes with Hgb level of more than 13.0 g/dL in ND participants is presented.

    Time frame: Up to week 52

  41. Number of Episodes With Hgb Level of More Than 13.0 g/dL in PD Participants

    Number of episodes with Hgb level of more than 13.0 g/dL in PD participants is presented.

    Time frame: Up to week 52

  42. Monthly Average Dose of Oral Iron During the Treatment Period in ND Participants

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron = Total oral iron dose (mg) / (duration in days / 30.4375 days). Monthly average dose of oral iron during the treatment period in ND participants is presented.

    Time frame: Up to Week 52

  43. Monthly Average Dose of Oral Iron During the Treatment Period in PD Participants

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron = Total oral iron dose (mg) / (duration in days / 30.4375 days). Monthly average dose of oral iron during the treatment period in PD participants is presented.

    Time frame: Up to Week 52

  44. Monthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in ND Participants

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron dose during the primary efficacy evaluation period (Weeks 40 to 52) = Total oral iron dose (mg) during the primary efficacy evaluation period / (duration in the period in days / 30.4375 days). Monthly average dose of oral iron during the primary efficacy evaluation period in ND participants is presented.

    Time frame: Weeks 40 to 52

  45. Monthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in PD Participants

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron dose during the primary efficacy evaluation period (Weeks 40 to 52) = Total oral iron dose (mg) during the primary efficacy evaluation period / (duration in the period in days / 30.4375 days). Monthly average dose of oral iron during the primary efficacy evaluation period in PD participants is presented.

    Time frame: Weeks 40 to 52

  46. Number of ND Participants Who Used Oral Iron During the Treatment Period

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of ND participants who used oral iron during the treatment period were summarized.

    Time frame: Up to week 52

  47. Number of PD Participants Who Used Oral Iron During the Treatment Period

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of PD participants who used oral iron during the treatment period were summarized.

    Time frame: Up to week 52

  48. Percentage of ND Participants Who Used Oral Iron During the Treatment Period

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of ND participants who used oral iron during the treatment period were summarized.

    Time frame: Up to week 52

  49. Percentage of PD Participants Who Used Oral Iron During the Treatment Period

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of PD participants who used oral iron during the treatment period were summarized.

    Time frame: Up to week 52

  50. Number of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of ND participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.

    Time frame: Weeks 40 to 52

  51. Number of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of PD participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.

    Time frame: Weeks 40 to 52

  52. Percentage of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of ND participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.

    Time frame: Weeks 40 to 52

  53. Percentage of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period

    Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of PD participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.

    Time frame: Weeks 40 to 52

  54. Change From Baseline in Ferritin in ND Participants

    Change from Baseline in Ferritin in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Ferritin is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.

    Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52

  55. Change From Baseline in Ferritin in PD Participants

    Change from Baseline in Ferritin in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Ferritin is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.

    Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52

  56. Percent Change From Baseline in Transferrin Saturation (TSAT) in ND Participants

    Percent change from Baseline in TSAT in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in TSAT is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.

    Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52

  57. Percent Change From Baseline in TSAT in PD Participants

    Percent change from Baseline in TSAT in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in TSAT is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.

    Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52

  58. Percent Change From Baseline in Hepcidin in ND Participants

    Percent change from Baseline in Hepcidin in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in Hepcidin is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.

    Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52

  59. Percent Change From Baseline in Hepcidin in PD Participants

    Percent change from Baseline in Hepcidin in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in Hepcidin is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.

    Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52

  60. Change From Baseline in Serum Iron in ND Participants

    Change from Baseline in serum iron in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Serum iron is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.

    Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52

  61. Change From Baseline in Serum Iron in PD Participants

    Change from Baseline in serum iron in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Serum iron is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.

    Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52

  62. Change From Baseline in Total Iron Binding Capacity (TIBC) in ND Participants

    Change from Baseline in TIBC in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in TIBC is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.

    Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52

  63. Change From Baseline in TIBC in PD Participants

    Change from Baseline in TIBC in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in TIBC is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.

    Time frame: Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52

  64. Area Under the Concentration-time Curve From Time Zero Extrapolated to 4 Hours (AUC[0-4]) of Daprodustat for All Dose Levels in ND and PD Participants

    Blood samples were collected at indicated timepoints. Pharmacokinetic (PK) parameters of Daprodustat were calculated using non-compartmental method. AUC (0-4) is presented for combined Week 12 and 24. Geometric mean and geometric coefficient of variation is presented. NA indicates that the data is not available since geometric coefficient of variation could not be calculated for a single participant.

    Time frame: 1, 2, 3 and 4 hours post dose at Weeks 12 and 24

  65. Maximum Observed Concentration (Cmax) of Daprodustat for All Dose Levels in ND and PD Participants

    Blood samples were collected at indicated timepoints. PK parameters of Daprodustat were calculated using non-compartmental method. Cmax is presented for combined Week 12 and 24. Geometric mean and geometric coefficient of variation is presented. NA indicates that the data is not available since geometric coefficient of variation could not be calculated for a single participant.

    Time frame: 1, 2, 3 and 4 hours post dose at Weeks 12 and 24

07

Results

Posted Nov 13, 2019
Limitations and caveats
A participant in ND daprodustat/ND epoetin beta pegol/PD daprodustat had data entry error with dose level. This had an impact on outcomes of dose level and number of dose adjustment.

Participant flow

This was an open-label, active-controlled, parallel-group, multi-center study to compare the efficacy (verification of non-inferiority) and safety of GSK1278863 (daprodustat) versus epoetin beta pegol in Japanese non-dialysis (ND) participants, including an open-label non-comparative cohort of peritoneal dialysis (PD) participants.

Participant flow — Overall Study
MilestoneDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND ParticipantsDaprodustat in PD Participants
Started14915056
Completed11111343
Not completed383713
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject510
Withdrew: Physician decision010
Withdrew: Needs maintenance/changes in dialysis16195
Withdrew: Cancer event130
Withdrew: Participant had renal transplant300
Withdrew: Met hemoglobin stopping criteria100
Withdrew: Adverse event12137

Outcome measures

PrimaryMean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants

The mean hemoglobin during the primary efficacy evaluation period in ND participants was estimated by a statistical model using Mixed Model Repeated Measures (MMRM).

Time frame:
Weeks 40 to 52
Reported as:
Mean · Grams per deciliter (g/dL)
Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants
Grams per deciliter (g/dL)Daprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Mean Hemoglobin (Hgb) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants11.97 ± 0.06111.86 ± 0.063
Statistical analysis
  • Daprodustat in ND Participants vs Epoetin Beta Pegol in ND Participants · Mixed model repeated measures (MMRM) · p = <.0001 (The p value on this table is one-sided and calculated for the non-inferiority assessment.) · Median difference (final values): 0.10 · 95% CI -0.07 to 0.28Analysis was performed by a MMRM with covariates of treatment, Baseline Hgb, visit, treatment-by-visit interaction and Baseline-by-visit interaction.
SecondaryNumber of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)

ND participants with observed mean Hgb within the target range during the primary efficacy evaluation period were summarized. Responders were defined as the participants with the mean Hgb within target range during the primary efficacy evaluation period.

Time frame:
Weeks 40 to 52
Reported as:
Count of participants · Participants
Number of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)
ParticipantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Responder8180
Non-Responder77
Statistical analysis
  • Daprodustat in ND Participants vs Epoetin Beta Pegol in ND Participants · Regression, Logistic · p = 0.4941 (The p value on this table is one-sided and calculated for the superiority assessment.) · Odds ratio (or): 1.01 · 95% CI 0.33 to 3.04Analysis was performed by logistic regression with covariates of treatment, Baseline Hgb, and Baseline ESA use.
SecondaryPercentage of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)

The percentage of ND participants with observed mean Hgb within the target range during the primary efficacy evaluation period was summarized. Responders were defined as the participants with the mean Hgb within target range during the primary efficacy evaluation period.

Time frame:
Weeks 40 to 52
Reported as:
Number · Percentage of participants
Percentage of ND Participants With Mean Hgb in the Target Range (11.0-13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52)
Percentage of participantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Responder9292
Non-Responder88
Statistical analysis
  • Daprodustat in ND Participants vs Epoetin Beta Pegol in ND Participants · Regression, Logistic · p = 0.4941 (The p value on this table is one-sided and calculated for the superiority assessment.) · Odds ratio (or): 1.01 · 95% CI 0.33 to 3.04Analysis was performed by logistic regression with covariates of treatment, Baseline Hgb, and Baseline ESA use.
SecondaryChange From Baseline in Hgb at Week 4 in ND Participants

Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb at Week 4 in ND participants is presented.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · g/dL
Change From Baseline in Hgb at Week 4 in ND Participants
g/dLDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Change From Baseline in Hgb at Week 4 in ND Participants0.47 ± 0.8780.26 ± 0.711
SecondaryChange From Baseline in Hgb at Week 4 in PD Participants

Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb at week 4 in PD participants is presented.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Mean · g/dL
Change From Baseline in Hgb at Week 4 in PD Participants
g/dLDaprodustat in PD Participants
Change From Baseline in Hgb at Week 4 in PD Participants-0.09 ± 0.899
SecondaryNumber of ND Participants by Hgb Change From Baseline Category at Week 4

Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Count of participants · Participants
Number of ND Participants by Hgb Change From Baseline Category at Week 4
ParticipantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
<=-2.012
>-2.0 and <=-1.043
>-1.0 and <=02833
>0 and <=1.04356
>1.0 and <=2.02915
>2.020
within +/- 1.07290
over +/- 2.031
SecondaryPercentage of ND Participants by Hgb Change From Baseline Category at Week 4

Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Number · Percentage of participants
Percentage of ND Participants by Hgb Change From Baseline Category at Week 4
Percentage of participantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
<=-2.012
>-2.0 and <=-1.043
>-1.0 and <=02630
>0 and <=1.04051
>1.0 and <=2.02714
>2.020
within +/- 1.06783
over +/- 2.031
SecondaryNumber of PD Participants by Hgb Change From Baseline Category at Week 4

Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Count of participants · Participants
Number of PD Participants by Hgb Change From Baseline Category at Week 4
ParticipantsDaprodustat in PD Participants
<=-2.00
>-2.0 and <=-1.010
>-1.0 and <=020
>0 and <=1.020
>1.0 and <=2.04
>2.01
within +/- 1.041
over +/- 2.01
SecondaryPercentage of PD Participants by Hgb Change From Baseline Category at Week 4

Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Number of participants by Hgb change from Baseline is categorized to \<=-2.0, \>-2.0 and \<=-1.0, \>-1.0 and \<=0, \>0 and \<=1.0, \>1.0 and \<=2.0, \>2.0 g/dL, then is additionally categorized to within +/- 1.0 g/dL and over +/- 2.0 g/dL. Number of participants have been included in more than one category at Week 4.

Time frame:
Baseline (Day 1) and Week 4
Reported as:
Number · Percentage of Participants
Percentage of PD Participants by Hgb Change From Baseline Category at Week 4
Percentage of ParticipantsDaprodustat in PD Participants
<=-2.00
>-2.0 and <=-1.018
>-1.0 and <=036
>0 and <=1.036
>1.0 and <=2.07
>2.02
within +/- 1.075
over +/- 2.02
SecondaryDaprodustat Dose Level by Visit in ND Participants

Daprodustat dose level at each assessment visit for ND participants is presented using 25th percentile (P25), median, and 75th percentile (P75).

Time frame:
Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44 and 48
Reported as:
Median · Milligrams per day (mg/day)
Daprodustat Dose Level by Visit in ND Participants
Milligrams per day (mg/day)Daprodustat in ND Participants
Day 1, n=1084.0 (2.0 to 4.0)
Week 4, n=1064.0 (2.0 to 6.0)
Week 8, n=1064.0 (2.0 to 6.0)
Week 12, n=1064.0 (2.0 to 6.0)
Week 16, n=1034.0 (2.0 to 6.0)
Week 20, n=1004.0 (2.0 to 8.0)
Week 24, n=964.0 (2.0 to 8.0)
Week 28, n=944.0 (2.0 to 8.0)
Week 32, n=924.0 (2.0 to 6.0)
Week 36, n=894.0 (2.0 to 6.0)
Week 40, n=884.0 (2.0 to 6.0)
Week 44, n=884.0 (2.0 to 7.0)
Week 48, n=874.0 (2.0 to 6.0)
SecondaryEpoetin Beta Pegol Dose Level by Visit in ND Participants

Dose of epoetin beta pegol at a scheduled visit was converted to dose per 4 weeks when the dose frequency was every 2 weeks. Epoetin beta pegol dose level at each assessment visit for ND participants is presented using 25th percentile (P25), median, and 75th percentile (P75).

Time frame:
Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44 and 48
Reported as:
Median · Micrograms per 4 weeks
Epoetin Beta Pegol Dose Level by Visit in ND Participants
Micrograms per 4 weeksEpoetin Beta Pegol in ND Participants
Day 1, n=10950.0 (50.0 to 50.0)
Week 4, n=10975.0 (50.0 to 100.0)
Week 8, n=107100.0 (50.0 to 100.0)
Week 12, n=105100.0 (50.0 to 150.0)
Week 16, n=10475.0 (25.0 to 150.0)
Week 20, n=10075.0 (50.0 to 150.0)
Week 24, n=9775.0 (50.0 to 150.0)
Week 28, n=9275.0 (50.0 to 150.0)
Week 32, n=9075.0 (50.0 to 150.0)
Week 36, n=8875.0 (75.0 to 150.0)
Week 40, n=8775.0 (50.0 to 150.0)
Week 44, n=84100.0 (62.5 to 150.0)
Week 48, n=82100.0 (75.0 to 150.0)
SecondaryDaprodustat Dose Level by Visit in PD Participants

Daprodustat dose level at each assessment visit for PD participants is presented using 25th percentile (P25), median, and 75th percentile (P75).

Time frame:
Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44 and 48
Reported as:
Median · mg/day
Daprodustat Dose Level by Visit in PD Participants
mg/dayDaprodustat in PD Participants
Day 1, n=554.0 (4.0 to 4.0)
Week 4, n=556.0 (4.0 to 6.0)
Week 8, n=526.0 (4.0 to 8.0)
Week 12, n=526.0 (4.0 to 8.0)
Week 16, n=516.0 (4.0 to 8.0)
Week 20, n=506.0 (4.0 to 12.0)
Week 24, n=488.0 (4.0 to 12.0)
Week 28, n=458.0 (4.0 to 8.0)
Week 32, n=456.0 (4.0 to 8.0)
Week 36, n=458.0 (4.0 to 12.0)
Week 40, n=446.0 (2.0 to 8.0)
Week 44, n=436.0 (2.0 to 8.0)
Week 48, n=436.0 (2.0 to 8.0)
SecondaryDuration of Treatment Interruption Due to Hgb >13 g/dL in ND Participants

The duration (in days) of treatment interruption due to Hgb \>13 g/dL per participant was summarized descriptively on participants with a period of treatment interruption due to Hgb \>13 g/dL.

Time frame:
Up to Week 52
Reported as:
Median · Days
Duration of Treatment Interruption Due to Hgb >13 g/dL in ND Participants
DaysDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Duration of Treatment Interruption Due to Hgb >13 g/dL in ND Participants28.0 (14 to 111)28.0 (26 to 113)
SecondaryDuration of Treatment Interruption Due to Hgb >13 g/dL in PD Participants

The duration (in days) of treatment interruption due to Hgb \>13 g/dL per participant was summarized descriptively on participants with a period of treatment interruption due to Hgb \>13 g/dL.

Time frame:
Up to Week 52
Reported as:
Median · Days
Duration of Treatment Interruption Due to Hgb >13 g/dL in PD Participants
DaysDaprodustat in PD Participants
Duration of Treatment Interruption Due to Hgb >13 g/dL in PD Participants28.0 (19 to 168)
SecondaryNumber of Dose Adjustments in ND Participants

Number of dose adjustments in ND participants is presented.

Time frame:
Up to Week 52
Reported as:
Median · Number of dose adjustments
Number of Dose Adjustments in ND Participants
Number of dose adjustmentsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Number of Dose Adjustments in ND Participants5.0 (0 to 9)6.0 (1 to 10)
SecondaryNumber of Dose Adjustments in PD Participants

Number of dose adjustments in PD participants is presented.

Time frame:
Up to Week 52
Reported as:
Median · Number of dose adjustments
Number of Dose Adjustments in PD Participants
Number of dose adjustmentsDaprodustat in PD Participants
Number of Dose Adjustments in PD Participants5.0 (0 to 11)
SecondaryHgb Values at Each Assessment Visit in ND Participants

Hgb values at each assessment visit for ND participants is presented.

Time frame:
Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Reported as:
Mean · g/dL
Hgb Values at Each Assessment Visit in ND Participants
g/dLDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Day 1, n=108,10910.48 ± 1.14010.68 ± 1.066
Week 4, n=107,10910.95 ± 1.12210.94 ± 1.024
Week 8, n=107,10911.19 ± 1.09211.34 ± 0.905
Week 12, n=106,10711.51 ± 1.02411.84 ± 0.880
Week 16, n=104,10511.90 ± 1.09112.07 ± 1.073
Week 20, n=102,10311.84 ± 0.90911.96 ± 0.820
Week 24, n=99,9911.87 ± 0.74011.80 ± 0.855
Week 28, n=96,9311.98 ± 0.84511.83 ± 0.859
Week 32, n=92,9012.03 ± 0.78511.80 ± 0.875
Week 36, n=92,8811.93 ± 0.73011.81 ± 0.810
Week 40, n=88,8711.88 ± 0.73512.00 ± 0.857
Week 44, n=88,8611.87 ± 0.86811.75 ± 0.763
Week 48, n=87,8312.05 ± 0.89611.80 ± 0.904
Week 52, n=87,8112.01 ± 1.00311.99 ± 0.930
SecondaryHgb Values at Each Assessment Visit in PD Participants

Hgb values at each assessment visit for PD participants is presented.

Time frame:
Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Reported as:
Mean · g/dL
Hgb Values at Each Assessment Visit in PD Participants
g/dLDaprodustat in PD Participants
Day 1, n=5510.85 ± 0.964
Week 4, n=5510.77 ± 1.239
Week 8, n=5410.83 ± 1.259
Week 12, n=5211.36 ± 1.097
Week 16, n=5111.42 ± 1.079
Week 20, n=5011.54 ± 0.807
Week 24, n=4911.69 ± 0.816
Week 28, n=4811.95 ± 1.038
Week 32, n=4512.07 ± 0.890
Week 36, n=4511.90 ± 0.839
Week 40, n=4412.12 ± 0.795
Week 44, n=4311.92 ± 0.824
Week 48, n=4312.10 ± 0.774
Week 52, n=4312.12 ± 0.699
SecondaryChange From Baseline in Hgb Values at Each Assessment Visit in ND Participants

Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb values at each assessment visit in ND participants is presented.

Time frame:
Baseline (Day 1), Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Reported as:
Mean · g/dL
Change From Baseline in Hgb Values at Each Assessment Visit in ND Participants
g/dLDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Week 4, n=107,1090.47 ± 0.8780.26 ± 0.711
Week 8, n=107,1090.71 ± 1.1220.66 ± 1.109
Week 12, n=106,1071.04 ± 1.3521.18 ± 1.384
Week 16, n=104,1051.45 ± 1.3761.40 ± 1.495
Week 20, n=102,1031.39 ± 1.3301.26 ± 1.336
Week 24, n=99,991.41 ± 1.3461.10 ± 1.295
Week 28, n=96,931.54 ± 1.3751.08 ± 1.151
Week 32, n=92,901.60 ± 1.3711.04 ± 1.299
Week 36, n=92,881.49 ± 1.2651.04 ± 1.294
Week 40, n=88,871.44 ± 1.3711.26 ± 1.304
Week 44, n=88,861.43 ± 1.4351.01 ± 1.131
Week 48, n=87,831.61 ± 1.3501.03 ± 1.172
Week 52, n=87,811.56 ± 1.5271.21 ± 1.432
SecondaryChange From Baseline in Hgb Values at Each Assessment Visit in PD Participants

Baseline Hgb value was the value from the Day 1 visit. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in Hgb values at each assessment visit in PD participants is presented.

Time frame:
Baseline (Day 1), Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Reported as:
Mean · g/dL
Change From Baseline in Hgb Values at Each Assessment Visit in PD Participants
g/dLDaprodustat in PD Participants
Week 4, n=55-0.09 ± 0.899
Week 8, n=54-0.06 ± 1.127
Week 12, n=520.44 ± 1.173
Week 16, n=510.52 ± 1.295
Week 20, n=500.63 ± 1.158
Week 24, n=490.74 ± 1.182
Week 28, n=481.00 ± 1.317
Week 32, n=451.13 ± 1.192
Week 36, n=450.95 ± 1.106
Week 40, n=441.13 ± 1.227
Week 44, n=430.90 ± 1.093
Week 48, n=431.08 ± 1.248
Week 52, n=431.10 ± 1.226
SecondaryNumber of ND Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit

Number of ND participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.

Time frame:
Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Reported as:
Count of participants · Participants
Number of ND Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit
ParticipantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Day 1, n=108,1092936
Week 4, n=107,1094348
Week 8, n=107,1096473
Week 12, n=106,1077885
Week 16, n=104,1058480
Week 20, n=102,1038885
Week 24, n=99,998685
Week 28, n=96,937773
Week 32, n=92,907967
Week 36, n=92,887970
Week 40, n=88,877872
Week 44, n=88,867168
Week 48, n=87,837562
Week 52, n=87,816759
SecondaryPercentage of ND Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit

Percentage of ND participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.

Time frame:
Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Reported as:
Number · Percentage of Participants
Percentage of ND Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit
Percentage of ParticipantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Day 1, n=108,1092733
Week 4, n=107,1094044
Week 8, n=107,1096067
Week 12, n=106,1077479
Week 16, n=104,1058176
Week 20, n=102,1038683
Week 24, n=99,998786
Week 28, n=96,938078
Week 32, n=92,908674
Week 36, n=92,888680
Week 40, n=88,878983
Week 44, n=88,868179
Week 48, n=87,838675
Week 52, n=87,817773
SecondaryNumber of PD Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit

Number of PD participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.

Time frame:
Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Reported as:
Count of participants · Participants
Number of PD Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit
ParticipantsDaprodustat in PD Participants
Day 1, n=5528
Week 4, n=5525
Week 8, n=5426
Week 12, n=5232
Week 16, n=5132
Week 20, n=5038
Week 24, n=4936
Week 28, n=4839
Week 32, n=4534
Week 36, n=4536
Week 40, n=4434
Week 44, n=4333
Week 48, n=4336
Week 52, n=4338
SecondaryPercentage of PD Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit

Percentage of PD participants with Hgb level within the target range (11.0 to 13.0 g/dL) are summarized at each assessment visit.

Time frame:
Day 1, Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and Week 52
Reported as:
Number · Percentage of Participants
Percentage of PD Participants Who Had Hgb Level Within the Target Range (11.0-13.0 g/dL) at Each Assessment Visit
Percentage of ParticipantsDaprodustat in PD Participants
Day 1, n=5551
Week 4, n=5545
Week 8, n=5448
Week 12, n=5262
Week 16, n=5163
Week 20, n=5076
Week 24, n=4973
Week 28, n=4881
Week 32, n=4576
Week 36, n=4580
Week 40, n=4477
Week 44, n=4377
Week 48, n=4384
Week 52, n=4388
SecondaryPercentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants

Mean percentage of time with Hgb within the target range (11.0 to 13.0 g/dL) is summarized during the primary efficacy evaluation period (Weeks 40 to 52).

Time frame:
Weeks 40 to 52
Reported as:
Mean · Percentage of time
Percentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants
Percentage of timeDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Percentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in ND Participants85.44 ± 22.47380.57 ± 25.973
SecondaryPercentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in PD Participants

Mean percentage of time with Hgb within the target range (11.0 to 13.0 g/dL) is summarized during the primary efficacy evaluation period (Weeks 40 to 52).

Time frame:
Weeks 40 to 52
Reported as:
Mean · Percentage of time
Percentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in PD Participants
Percentage of timeDaprodustat in PD Participants
Percentage of Time With Hgb Within the Target Range (11.0 to 13.0 g/dL) During the Primary Efficacy Evaluation Period (Weeks 40 to 52) in PD Participants85.73 ± 19.974
SecondaryTime to Reach the Lower Target Hgb Level (11.0 g/dL) in ND Participants

The time (in days) to reach the lower target Hgb level (11.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method. Participants who did not reach the lower Hgb target were considered as censored cases. Participants who were randomized as Hgb \>= 11.0 g/dL were excluded in this summary.

Time frame:
Up to week 52
Reported as:
Median · Days
Time to Reach the Lower Target Hgb Level (11.0 g/dL) in ND Participants
DaysDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Time to Reach the Lower Target Hgb Level (11.0 g/dL) in ND Participants58.0 (29.0 to 87.0)57.0 (29.0 to 85.0)
SecondaryTime to Reach the Lower Target Hgb Level (11.0 g/dL) in PD Participants

The time (in days) to reach the lower target Hgb level (11.0 g/dL) was summarized using 25th percentile (P25), median, and 75th percentile (P75) by Kaplan-Meier method. Participants who did not reach the lower Hgb target were considered as censored cases. Participants who were randomized as Hgb \>= 11.0 g/dL were excluded in this summary.

Time frame:
Up to week 52
Reported as:
Median · Days
Time to Reach the Lower Target Hgb Level (11.0 g/dL) in PD Participants
DaysDaprodustat in PD Participants
Time to Reach the Lower Target Hgb Level (11.0 g/dL) in PD Participants84.0 (29.0 to 141.0)
SecondaryNumber of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL

Number of ND participants who had an Hgb level of less than 7.5 g/dL is presented.

Time frame:
Up to week 52
Reported as:
Count of participants · Participants
Number of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL
ParticipantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Number of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL10
SecondaryPercentage of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL

Percentage of ND participants who had an Hgb level of less than 7.5 g/dL is presented.

Time frame:
Up to week 52
Reported as:
Number · Percentage of participants
Percentage of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL
Percentage of participantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Percentage of ND Participants Who Had an Hgb Level of Less Than 7.5 g/dL10
SecondaryNumber of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL

Number of PD participants who had an Hgb level of less than 7.5 g/dL is presented.

Time frame:
Up to week 52
Reported as:
Count of participants · Participants
Number of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL
ParticipantsDaprodustat in PD Participants
Number of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL0
SecondaryPercentage of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL

Percentage of PD participants who had an Hgb level of less than 7.5 g/dL is presented.

Time frame:
Up to week 52
Reported as:
Number · Percentage of participants
Percentage of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL
Percentage of participantsDaprodustat in PD Participants
Percentage of PD Participants Who Had an Hgb Level of Less Than 7.5 g/dL0
SecondaryNumber of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

Number of ND participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.

Time frame:
Up to week 52
Reported as:
Count of participants · Participants
Number of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
ParticipantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Number of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks1711
SecondaryPercentage of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

Percentage of ND participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.

Time frame:
Up to week 52
Reported as:
Number · Percentage of participants
Percentage of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
Percentage of participantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Percentage of ND Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks1610
SecondaryNumber of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

Number of PD participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.

Time frame:
Up to week 52
Reported as:
Count of participants · Participants
Number of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
ParticipantsDaprodustat in PD Participants
Number of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks11
SecondaryPercentage of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks

Percentage of PD participants who had an Hgb increase of more than 2 g/dL over any 4 weeks is presented.

Time frame:
Up to week 52
Reported as:
Number · Percentage of participants
Percentage of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks
Percentage of participantsDaprodustat in PD Participants
Percentage of PD Participants Who Had an Hgb Increase of More Than 2 g/dL Over Any 4 Weeks20
SecondaryNumber of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL

Number of ND participants who had an Hgb level of more than 13.0 g/dL is presented.

Time frame:
Up to week 52
Reported as:
Count of participants · Participants
Number of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL
ParticipantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Number of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL4952
SecondaryPercentage of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL

Percentage of ND participants who had an Hgb level of more than 13.0 g/dL is presented.

Time frame:
Up to week 52
Reported as:
Number · Percentage of participants
Percentage of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL
Percentage of participantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Percentage of ND Participants Who Had an Hgb Level of More Than 13.0 g/dL4548
SecondaryNumber of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL

Number of PD participants who had an Hgb level of more than 13.0 g/dL is presented.

Time frame:
Up to week 52
Reported as:
Count of participants · Participants
Number of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL
ParticipantsDaprodustat in PD Participants
Number of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL28
SecondaryPercentage of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL

Percentage of PD participants who had an Hgb level of more than 13.0 g/dL is presented.

Time frame:
Up to week 52
Reported as:
Number · Percentage of participants
Percentage of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL
Percentage of participantsDaprodustat in PD Participants
Percentage of PD Participants Who Had an Hgb Level of More Than 13.0 g/dL51
SecondaryNumber of Episodes With Hgb Level of More Than 13.0 g/dL in ND Participants

Number of episodes with Hgb level of more than 13.0 g/dL in ND participants is presented.

Time frame:
Up to week 52
Reported as:
Number · Episodes
Number of Episodes With Hgb Level of More Than 13.0 g/dL in ND Participants
EpisodesDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Number of Episodes With Hgb Level of More Than 13.0 g/dL in ND Participants7688
SecondaryNumber of Episodes With Hgb Level of More Than 13.0 g/dL in PD Participants

Number of episodes with Hgb level of more than 13.0 g/dL in PD participants is presented.

Time frame:
Up to week 52
Reported as:
Number · Episodes
Number of Episodes With Hgb Level of More Than 13.0 g/dL in PD Participants
EpisodesDaprodustat in PD Participants
Number of Episodes With Hgb Level of More Than 13.0 g/dL in PD Participants43
SecondaryMonthly Average Dose of Oral Iron During the Treatment Period in ND Participants

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron = Total oral iron dose (mg) / (duration in days / 30.4375 days). Monthly average dose of oral iron during the treatment period in ND participants is presented.

Time frame:
Up to Week 52
Reported as:
Mean · Milligrams
Monthly Average Dose of Oral Iron During the Treatment Period in ND Participants
MilligramsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Monthly Average Dose of Oral Iron During the Treatment Period in ND Participants837.37 ± 1209.100747.04 ± 1130.767
SecondaryMonthly Average Dose of Oral Iron During the Treatment Period in PD Participants

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron = Total oral iron dose (mg) / (duration in days / 30.4375 days). Monthly average dose of oral iron during the treatment period in PD participants is presented.

Time frame:
Up to Week 52
Reported as:
Mean · Milligrams
Monthly Average Dose of Oral Iron During the Treatment Period in PD Participants
MilligramsDaprodustat in PD Participants
Monthly Average Dose of Oral Iron During the Treatment Period in PD Participants2468.68 ± 5418.767
SecondaryMonthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in ND Participants

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron dose during the primary efficacy evaluation period (Weeks 40 to 52) = Total oral iron dose (mg) during the primary efficacy evaluation period / (duration in the period in days / 30.4375 days). Monthly average dose of oral iron during the primary efficacy evaluation period in ND participants is presented.

Time frame:
Weeks 40 to 52
Reported as:
Mean · Milligrams
Monthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in ND Participants
MilligramsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Monthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in ND Participants967.41 ± 1854.896777.69 ± 1639.331
SecondaryMonthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in PD Participants

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. Monthly average oral iron dose during the primary efficacy evaluation period (Weeks 40 to 52) = Total oral iron dose (mg) during the primary efficacy evaluation period / (duration in the period in days / 30.4375 days). Monthly average dose of oral iron during the primary efficacy evaluation period in PD participants is presented.

Time frame:
Weeks 40 to 52
Reported as:
Mean · Milligrams
Monthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in PD Participants
MilligramsDaprodustat in PD Participants
Monthly Average Dose of Oral Iron During the Primary Efficacy Evaluation Period in PD Participants3038.67 ± 6239.034
SecondaryNumber of ND Participants Who Used Oral Iron During the Treatment Period

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of ND participants who used oral iron during the treatment period were summarized.

Time frame:
Up to week 52
Reported as:
Count of participants · Participants
Number of ND Participants Who Used Oral Iron During the Treatment Period
ParticipantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Number of ND Participants Who Used Oral Iron During the Treatment Period5649
SecondaryNumber of PD Participants Who Used Oral Iron During the Treatment Period

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of PD participants who used oral iron during the treatment period were summarized.

Time frame:
Up to week 52
Reported as:
Count of participants · Participants
Number of PD Participants Who Used Oral Iron During the Treatment Period
ParticipantsDaprodustat in PD Participants
Number of PD Participants Who Used Oral Iron During the Treatment Period33
SecondaryPercentage of ND Participants Who Used Oral Iron During the Treatment Period

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of ND participants who used oral iron during the treatment period were summarized.

Time frame:
Up to week 52
Reported as:
Number · Percentage of participants
Percentage of ND Participants Who Used Oral Iron During the Treatment Period
Percentage of participantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Percentage of ND Participants Who Used Oral Iron During the Treatment Period5245
SecondaryPercentage of PD Participants Who Used Oral Iron During the Treatment Period

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of PD participants who used oral iron during the treatment period were summarized.

Time frame:
Up to week 52
Reported as:
Number · Percentage of participants
Percentage of PD Participants Who Used Oral Iron During the Treatment Period
Percentage of participantsDaprodustat in PD Participants
Percentage of PD Participants Who Used Oral Iron During the Treatment Period60
SecondaryNumber of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of ND participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.

Time frame:
Weeks 40 to 52
Reported as:
Count of participants · Participants
Number of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period
ParticipantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Number of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period3428
SecondaryNumber of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The number of PD participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.

Time frame:
Weeks 40 to 52
Reported as:
Count of participants · Participants
Number of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period
ParticipantsDaprodustat in PD Participants
Number of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period22
SecondaryPercentage of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of ND participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.

Time frame:
Weeks 40 to 52
Reported as:
Number · Percentage of participants
Percentage of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period
Percentage of participantsDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Percentage of ND Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period3932
SecondaryPercentage of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period

Supplemental iron therapy were received by participants if required during treatment period. Participants who used ferric citrate were counted as oral iron use. The percentage of PD participants who used oral iron during the primary efficacy evaluation period (Weeks 40 to 52) were summarized.

Time frame:
Weeks 40 to 52
Reported as:
Number · Percentage of participants
Percentage of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period
Percentage of participantsDaprodustat in PD Participants
Percentage of PD Participants Who Used Oral Iron During the Primary Efficacy Evaluation Period50
SecondaryChange From Baseline in Ferritin in ND Participants

Change from Baseline in Ferritin in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Ferritin is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.

Time frame:
Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Reported as:
Mean · Micrograms per liter (µg/L)
Change From Baseline in Ferritin in ND Participants
Micrograms per liter (µg/L)Daprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Week 4, n=107,109-41.4 (-53.7 to -29.2)-29.0 (-41.1 to -16.9)
Week 16, n=104,105-83.4 (-102.8 to -64.0)-29.3 (-48.6 to -10.0)
Week 28, n=96,93-80.1 (-96.4 to -63.8)-16.6 (-33.1 to -0.1)
Week 40, n=88,87-56.3 (-79.1 to -33.4)-16.0 (-38.9 to 6.9)
Week 52, n=87,81-42.7 (-68.9 to -16.4)-14.0 (-40.9 to 13.0)
SecondaryChange From Baseline in Ferritin in PD Participants

Change from Baseline in Ferritin in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Ferritin is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.

Time frame:
Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Reported as:
Mean · µg/L
Change From Baseline in Ferritin in PD Participants
µg/LDaprodustat in PD Participants
Week 4, n=55-36.4 (-49.8 to -23.1)
Week 16, n=51-81.8 (-103.7 to -59.9)
Week 28, n=48-89.1 (-111.6 to -66.7)
Week 40, n=44-74.6 (-112.7 to -36.4)
Week 52, n=43-63.6 (-101.0 to -26.2)
SecondaryPercent Change From Baseline in Transferrin Saturation (TSAT) in ND Participants

Percent change from Baseline in TSAT in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in TSAT is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.

Time frame:
Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in Transferrin Saturation (TSAT) in ND Participants
Percent changeDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Week 4, n=107,109-12.4 (-17.6 to -6.8)-5.4 (-11.1 to 0.5)
Week 16, n=104,105-16.3 (-21.6 to -10.6)-0.3 (-6.6 to 6.5)
Week 28, n=96,93-17.5 (-23.2 to -11.4)10.6 (2.9 to 18.9)
Week 40, n=88,87-11.2 (-17.8 to -4.1)12.5 (4.1 to 21.5)
Week 52, n=87,81-11.7 (-18.3 to -4.6)7.0 (-1.3 to 15.9)
SecondaryPercent Change From Baseline in TSAT in PD Participants

Percent change from Baseline in TSAT in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in TSAT is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.

Time frame:
Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in TSAT in PD Participants
Percent changeDaprodustat in PD Participants
Week 4, n=55-19.2 (-27.2 to -10.4)
Week 16, n=51-29.1 (-36.9 to -20.5)
Week 28, n=48-22.6 (-30.4 to -14.0)
Week 40, n=44-19.5 (-28.3 to -9.5)
Week 52, n=43-14.7 (-25.4 to -2.6)
SecondaryPercent Change From Baseline in Hepcidin in ND Participants

Percent change from Baseline in Hepcidin in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in Hepcidin is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.

Time frame:
Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in Hepcidin in ND Participants
Percent changeDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Week 4, n=99,100-49.13 (-54.63 to -42.97)-19.20 (-27.82 to -9.55)
Week 16, n=86,99-55.67 (-61.60 to -48.82)-3.73 (-15.95 to 10.27)
Week 28, n=81,85-56.67 (-62.53 to -49.90)7.61 (-6.75 to 24.18)
Week 40, n=76,80-47.77 (-55.10 to -39.23)9.54 (-5.62 to 27.12)
Week 52, n=76,74-45.27 (-54.32 to -34.43)10.13 (-8.27 to 32.21)
SecondaryPercent Change From Baseline in Hepcidin in PD Participants

Percent change from Baseline in Hepcidin in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Percent change from Baseline was calculated as 100\*(exponential \[mean change on log scale\]-1). Adjusted geometric mean and 95% confidence interval for percent change from Baseline in Hepcidin is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.

Time frame:
Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Reported as:
Geometric mean · Percent change
Percent Change From Baseline in Hepcidin in PD Participants
Percent changeDaprodustat in PD Participants
Week 4, n=53-49.79 (-58.57 to -39.15)
Week 16, n=48-62.59 (-69.95 to -53.42)
Week 28, n=39-65.37 (-72.61 to -56.22)
Week 40, n=39-67.91 (-76.10 to -56.91)
Week 52, n=40-54.77 (-66.82 to -38.33)
SecondaryChange From Baseline in Serum Iron in ND Participants

Change from Baseline in serum iron in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Serum iron is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.

Time frame:
Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Reported as:
Mean · Micromoles per liter (µmol/L)
Change From Baseline in Serum Iron in ND Participants
Micromoles per liter (µmol/L)Daprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Week 4, n=107,1090.5 (-0.6 to 1.5)-0.8 (-1.8 to 0.2)
Week 16, n=104,1050.3 (-0.8 to 1.3)0.6 (-0.4 to 1.6)
Week 28, n=96,930.3 (-0.8 to 1.5)2.0 (0.8 to 3.1)
Week 40, n=88,870.9 (-0.2 to 2.1)1.8 (0.6 to 2.9)
Week 52, n=87,810.7 (-0.4 to 1.8)1.1 (-0.1 to 2.2)
SecondaryChange From Baseline in Serum Iron in PD Participants

Change from Baseline in serum iron in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in Serum iron is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.

Time frame:
Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Reported as:
Mean · µmol/L
Change From Baseline in Serum Iron in PD Participants
µmol/LDaprodustat in PD Participants
Week 4, n=55-1.2 (-2.7 to 0.4)
Week 16, n=51-2.4 (-3.8 to -1.1)
Week 28, n=48-1.0 (-2.5 to 0.5)
Week 40, n=44-0.4 (-1.9 to 1.2)
Week 52, n=431.0 (-1.9 to 3.9)
SecondaryChange From Baseline in Total Iron Binding Capacity (TIBC) in ND Participants

Change from Baseline in TIBC in ND participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in TIBC is presented. For adjusted values, analysis was performed by MMRM with covariates of treatment, Baseline, visit, treatment-by-visit interaction and Baseline-by-visit interaction.

Time frame:
Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Reported as:
Mean · µmol/L
Change From Baseline in Total Iron Binding Capacity (TIBC) in ND Participants
µmol/LDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND Participants
Week 4, n=107,1096.9 (6.2 to 7.7)0.5 (-0.2 to 1.3)
Week 16, n=104,1059.9 (8.7 to 11.0)1.9 (0.8 to 3.1)
Week 28, n=96,939.9 (8.7 to 11.1)1.4 (0.2 to 2.6)
Week 40, n=88,878.0 (6.6 to 9.4)0.2 (-1.2 to 1.7)
Week 52, n=87,817.8 (6.3 to 9.3)0.1 (-1.4 to 1.7)
SecondaryChange From Baseline in TIBC in PD Participants

Change from Baseline in TIBC in PD participants was summarized at each assessment visit. The Baseline value was the latest pre-dose assessment (Day 1 pre-dose). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Adjusted mean and 95% confidence interval for change from Baseline in TIBC is presented. For adjusted values, analysis was performed by MMRM with covariates of Baseline, visit and Baseline-by-visit interaction.

Time frame:
Baseline (Day 1 pre-dose) and Weeks 4, 16, 28, 40 and 52
Reported as:
Mean · µmol/L
Change From Baseline in TIBC in PD Participants
µmol/LDaprodustat in PD Participants
Week 4, n=556.9 (5.7 to 8.0)
Week 16, n=519.5 (7.7 to 11.3)
Week 28, n=4811.0 (8.8 to 13.2)
Week 40, n=4411.0 (8.0 to 14.0)
Week 52, n=439.6 (6.8 to 12.5)
SecondaryArea Under the Concentration-time Curve From Time Zero Extrapolated to 4 Hours (AUC[0-4]) of Daprodustat for All Dose Levels in ND and PD Participants

Blood samples were collected at indicated timepoints. Pharmacokinetic (PK) parameters of Daprodustat were calculated using non-compartmental method. AUC (0-4) is presented for combined Week 12 and 24. Geometric mean and geometric coefficient of variation is presented. NA indicates that the data is not available since geometric coefficient of variation could not be calculated for a single participant.

Time frame:
1, 2, 3 and 4 hours post dose at Weeks 12 and 24
Reported as:
Geometric mean · Hour*nanogram per milliliter
Area Under the Concentration-time Curve From Time Zero Extrapolated to 4 Hours (AUC[0-4]) of Daprodustat for All Dose Levels in ND and PD Participants
Hour*nanogram per milliliterDaprodustat 1 mgDaprodustat 2 mgDaprodustat 4 mgDaprodustat 6 mgDaprodustat 8 mgDaprodustat 12 mgDaprodustat 18 mgDaprodustat 24 mg
Area Under the Concentration-time Curve From Time Zero Extrapolated to 4 Hours (AUC[0-4]) of Daprodustat for All Dose Levels in ND and PD Participants35.3199 ± 38.463.0175 ± 89.8101.9293 ± 96.5152.4966 ± 83.2167.6515 ± 105.9190.0962 ± 65.9435.6847 ± 131.7404.0567 ± NA
SecondaryMaximum Observed Concentration (Cmax) of Daprodustat for All Dose Levels in ND and PD Participants

Blood samples were collected at indicated timepoints. PK parameters of Daprodustat were calculated using non-compartmental method. Cmax is presented for combined Week 12 and 24. Geometric mean and geometric coefficient of variation is presented. NA indicates that the data is not available since geometric coefficient of variation could not be calculated for a single participant.

Time frame:
1, 2, 3 and 4 hours post dose at Weeks 12 and 24
Reported as:
Geometric mean · Nanogram per milliliter
Maximum Observed Concentration (Cmax) of Daprodustat for All Dose Levels in ND and PD Participants
Nanogram per milliliterDaprodustat 1 mgDaprodustat 2 mgDaprodustat 4 mgDaprodustat 6 mgDaprodustat 8 mgDaprodustat 12 mgDaprodustat 18 mgDaprodustat 24 mg
Maximum Observed Concentration (Cmax) of Daprodustat for All Dose Levels in ND and PD Participants17.6522 ± 36.535.0709 ± 91.258.6098 ± 83.281.1851 ± 82.691.0731 ± 95.494.1242 ± 73.3197.9290 ± 159.6226.0000 ± NA

Adverse events

Collected over On-therapy serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment up to Week 52 for both ND and PD participants.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daprodustat in ND Participants1/149 (0.7%)34/149 (22.8%)85/149 (57%)
Epoetin Beta Pegol in ND Participants2/150 (1.3%)43/150 (28.7%)91/150 (60.7%)
Daprodustat in PD Participants0/56 (0%)26/56 (46.4%)41/56 (73.2%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND ParticipantsDaprodustat in PD Participants
PeritonitisInfections and infestations0/1490/1509/56
Renal impairmentRenal and urinary disorders5/14911/1500/56
Cardiac failure congestiveCardiac disorders0/1495/1503/56
Chronic kidney diseaseRenal and urinary disorders6/1498/1500/56
End stage renal diseaseRenal and urinary disorders3/1490/1500/56
Cardiac failureCardiac disorders0/1491/1501/56
Prinzmetal anginaCardiac disorders0/1490/1501/56
DehydrationMetabolism and nutrition disorders0/1492/1501/56
Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1490/1501/56
DiarrhoeaGastrointestinal disorders0/1490/1501/56
Most frequent other events
Showing 10 of 20
Most frequent other events
EventDaprodustat in ND ParticipantsEpoetin Beta Pegol in ND ParticipantsDaprodustat in PD Participants
NasopharyngitisInfections and infestations49/14956/15016/56
Catheter site infectionInfections and infestations0/1490/1509/56
DiarrhoeaGastrointestinal disorders0/1490/1507/56
ConstipationGastrointestinal disorders10/14918/1500/56
NauseaGastrointestinal disorders0/1490/1506/56
Device related infectionInfections and infestations0/1490/1505/56
Gastrooesophageal reflux diseaseGastrointestinal disorders0/1490/1505/56
HypertensionVascular disorders4/1498/1505/56
PruritusSkin and subcutaneous tissue disorders12/1495/1500/56
Back painMusculoskeletal and connective tissue disorders11/14911/1504/56

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Daprodustat in ND ParticipantsEpoetin Beta Pegol in ND ParticipantsDaprodustat in PD ParticipantsTotal
Mean68.2 ± 11.5770.3 ± 9.0964.4 ± 9.6468.5 ± 10.45
Sex: Female, Male
Sex: Female, Male(Participants)Daprodustat in ND ParticipantsEpoetin Beta Pegol in ND ParticipantsDaprodustat in PD ParticipantsTotal
Female535812123
Male969244232
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Count of Participants)Daprodustat in ND ParticipantsEpoetin Beta Pegol in ND ParticipantsDaprodustat in PD ParticipantsTotal
Asian- Japanese Heritage14915056355
08

Study locations

56 sites
  • GSK Investigational Site
    Aichi, 453-8566, Japan
  • GSK Investigational Site
    Aichi, 455-8530, Japan
  • GSK Investigational Site
    Aichi, 457-8511, Japan
  • GSK Investigational Site
    Aichi, 486-8510, Japan
  • GSK Investigational Site
    Chiba, 260-8712, Japan
  • GSK Investigational Site
    Chiba, 278-0004, Japan
  • GSK Investigational Site
    Ehime, 790-0024, Japan
  • GSK Investigational Site
    Fukui, 910-8526, Japan
  • GSK Investigational Site
    Fukuoka, 802-8555, Japan
  • GSK Investigational Site
    Fukuoka, 820-8505, Japan
  • GSK Investigational Site
    Fukushima, 963-8052, Japan
  • GSK Investigational Site
    Gifu, 500-8523, Japan
  • GSK Investigational Site
    Gifu, 500-8717, Japan
  • GSK Investigational Site
    Hiroshima, 720-0838, Japan
  • GSK Investigational Site
    Hokkaido, 007-0803, Japan
  • GSK Investigational Site
    Hokkaido, 060-0033, Japan
  • GSK Investigational Site
    Hokkaido, 065-8611, Japan
  • GSK Investigational Site
    Hokkaido, 073-0022, Japan
  • GSK Investigational Site
    Hokkaido, 073-0196, Japan
  • GSK Investigational Site
    Ibaraki, 302-0022, Japan
  • GSK Investigational Site
    Ibaraki, 306-0433, Japan
  • GSK Investigational Site
    Ibaraki, 310-0015, Japan
  • GSK Investigational Site
    Ishikawa, 920-0353, Japan
  • GSK Investigational Site
    Ishikawa, 920-8530, Japan
  • GSK Investigational Site
    Iwate, 020-0066, Japan
  • GSK Investigational Site
    Kagoshima, 890-0073, Japan
  • GSK Investigational Site
    Kagoshima, 893-0024, Japan
  • GSK Investigational Site
    Kagoshima, 899-5431, Japan
  • GSK Investigational Site
    Kanagawa, 210-0852, Japan
  • GSK Investigational Site
    Kanagawa, 234-8503, Japan
  • GSK Investigational Site
    Kanagawa, 242-0018, Japan
  • GSK Investigational Site
    Kanagawa, 251-8550, Japan
  • GSK Investigational Site
    Kumamoto, 861-8520, Japan
  • GSK Investigational Site
    Kumamoto, 862-8505, Japan
  • GSK Investigational Site
    Kyoto, 604-8845, Japan
  • GSK Investigational Site
    Kyoto, 611-0041, Japan
  • GSK Investigational Site
    Kyoto, 612-8555, Japan
  • GSK Investigational Site
    Nagano, 396-8555, Japan
  • GSK Investigational Site
    Nagano, 399-8292, Japan
  • GSK Investigational Site
    Oita, 874-0011, Japan
  • GSK Investigational Site
    Osaka, 530-0012, Japan
  • GSK Investigational Site
    Osaka, 530-8480, Japan
  • GSK Investigational Site
    Osaka, 555-0001, Japan
  • GSK Investigational Site
    Osaka, 558-8558, Japan
  • GSK Investigational Site
    Osaka, 586-8521, Japan
  • GSK Investigational Site
    Osaka, 591-8025, Japan
  • GSK Investigational Site
    Saitama, 330-8553, Japan
  • GSK Investigational Site
    Saitama, 335-0023, Japan
  • GSK Investigational Site
    Shiga, 523-0082, Japan
  • GSK Investigational Site
    Shizuoka, 425-8505, Japan
  • GSK Investigational Site
    Tokushima, 770-0011, Japan
  • GSK Investigational Site
    Tokyo, 141-8625, Japan
  • GSK Investigational Site
    Tottori, 683-0002, Japan
  • GSK Investigational Site
    Toyama, 932-8503, Japan
  • GSK Investigational Site
    Toyama, 937-0042, Japan
  • GSK Investigational Site
    Toyama, 938-8502, Japan
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Nangaku M, Hamano T, Akizawa T, Tsubakihara Y, Nagai R, Okuda N, Kurata K, Nagakubo T, Jones NP, Endo Y, Cobitz AR. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial. Am J Nephrol. 2021;52(1):26-35. doi: 10.1159/000513103. Epub 2021 Feb 9. PubMed 33561857 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (copy the URL below to your browser)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Oct 2018, 28 months.

Results were first posted in Nov 2019, 1 year after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 28 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2016
First posted
Jun 7, 2016
StartActual
Jun 6, 2016
Primary completionActual
Oct 26, 2018
CompletionActual
Oct 26, 2018
Results first posted
Nov 13, 2019
Last update
May 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02791763
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 7, 2016
Start date
Jun 6, 2016
Primary completion
Oct 26, 2018
Completion
Oct 26, 2018
Results posted
Nov 13, 2019
Last update
May 18, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion